Date: 2017-02-27
Type of information: Development agreement
Compound: lentiviral vectors
Company: Molmed (Italy) Rocket Pharma (USA - NY)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: development - manufacturing - production - services contract
Action mechanism: gene therapy
Disease: Fanconi anemia
Details:
- • On February 27, 2017, MolMed and Rocket Pharma signed a development and manufacturing service agreement on a gene therapy product for the treatment of Fanconi anemia. Rocket Pharma is a US gene therapy company with both an advancing clinical program and several preclinical programs focused on developing curative treatments for rare
genetic conditions with high unmet need. Pursuant to this agreement, MolMed will develop and manufacture the lentiviral vectors to be used for the ex vivo transduction of hematopoietic stem cells, as part of the manufacturing process of Rocket’s cellular therapy products intended for clinical trials and in related research and development activities.
Financial terms:
Latest news:
Is general: Yes
